CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.

Name: Αlpha¹ Rigor Record — CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.
Item: CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.
Rating: 59
Author: Αlpha¹

St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, Papas A, Devauchelle-Pensec V, Wang L, Xu W, Pham TH, Sikora K, Rees WA, Alevizos I

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 2 high issues for “CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
StatisticsStatistic did not reproduce−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 12 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced4 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-designed and transparently reported phase 2 randomized controlled trial. The paper demonstrates strong scientific premise, rigorous methodology, and comprehensive reporting across all eight dimensions. Minor copyediting issues and a few reporting gaps (e.g., explicit CONSORT statement, missing data handling) do not undermine the overall integrity.

Both reviewers independently scored all eight dimensions and agreed on every status, indicating high sampling stability. The study is an interventional clinical trial; all non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification component checked only a subset of tests (3), and one inconsistency was noted but not detailed; this is a caveat for the statistical analysis pass.

7 major claims checked against the paper's own evidence: 3 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks. 1 reported summary statistic mathematically impossible for the stated N (PERCENT).

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior work on the CD40/CD40L pathway's role in SjD, including upregulation in salivary glands and elevated soluble CD40L in sera. It also acknowledges the failure of first-generation anti-CD40L mAbs due to thromboembolic complications and explains how DAZ's Tn3 scaffold avoids this. The rationale for testing DAZ in two distinct populations is clearly linked to the unmet need and the pathway's importance.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on the CD40/CD40L pathway in SjD and the limitations of prior anti-CD40L therapies, and logically links this to the study objectives.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“The CD40/CD40 ligand (CD40L) pathway plays a prominent role in driving innate and humoral immune responses and has been implicated in the pathophysiology of a variety of autoimmune diseases.”

direct quote[Introduction, paragraph 3]

“To circumvent this problem, DAZ antigen-binding sites were engineered into a Tn3 scaffold, a non-mAb platform, which lacked an Fc region.”